Reduced intensity allogeneic stem cell transplant with anti‐thymocyte globulin and post‐transplant cyclophosphamide in acute myeloid leukemia
María Queralt Salas(Canary Institute of Cancer Research), Auro Viswabandya(Princess Margaret Cancer Centre), Jeffrey H. Lipton(Princess Margaret Cancer Centre), Shruti Prem(University Health Network), David Loach(University Health Network), Rajat Kumar(University Health Network), Arjun Law(University of Toronto), Eshetu G. Atenafu(Princess Margaret Cancer Centre), Fotios V. Michelis(Princess Margaret Cancer Centre), Jonas Mattsson(University Health Network), Zeyad Al‐Shaibani(University Health Network), Wilson Lam(Princess Margaret Cancer Centre), Dennis Kim(Princess Margaret Cancer Centre)
Cited by 22
Related Papers
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
|Annals of Oncology|2019|282
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
|Oncotarget|2017|187
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
|Biology of Blood and Marrow Transplantation|2015|142